TRIMTECH Therapeutics (TRIMTECH or the Company), a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million). The financing was led by Johnson & Johnson’s corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc. (“JJDC”), and BGF, who join existing investors. This new funding will support the Company as it progresses its proprietary platforms and differentiated portfolio.

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the appointment of Dr Mike Hutton to its Scientific Advisory Board (SAB). Mike will provide expert guidance to support the development of the Company’s targeted protein degradation (TPD) TRIMTAC™ and TRIMGLUE™ pipeline, including for Alzheimer’s and Parkinson’s disease targets.

TRIMTECH Therapeutics, a biotech company creating novel, small molecule therapeutics that selectively degrade protein aggregates, to combat neurodegenerative diseases, today announced the formation of its Scientific Advisory Board (SAB).